TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Alliance Foundation Trials, LLC.
Adicet Therapeutics
Northwestern University
Acerta Pharma BV
Takeda
Fate Therapeutics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Novartis
Galapagos NV
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
The Lymphoma Academic Research Organisation
Northwestern University
Baylor College of Medicine
Regeneron Pharmaceuticals
Eli Lilly and Company
Dana-Farber Cancer Institute
Massachusetts General Hospital
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Centre Henri Becquerel
University of Rochester
Washington University School of Medicine
University of Pennsylvania
UNC Lineberger Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Institute of Hematology & Blood Diseases Hospital, China
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Celgene
Memorial Sloan Kettering Cancer Center
Pharmacyclics Switzerland GmbH
Regeneron Pharmaceuticals
Medical College of Wisconsin
University of Washington
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Chinese PLA General Hospital
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
City of Hope Medical Center
Wake Forest University Health Sciences